130 results on '"Marquez-Rodas, Ivan"'
Search Results
2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis
3. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry
4. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
5. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
6. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
7. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
8. 770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients
9. Chemokine profiling of melanoma-macrophage crosstalk identifies CCL8 and CCL15 as prognostic factors in cutaneous melanoma
10. Supplementary Data 1 from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
11. Data from Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
12. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
13. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
14. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
15. Immunotherapeutic effects of intratumoral nanoplexed poly I:C
16. Evolution of pancreatic ductal adenocarcinoma diagnosis during the last decade.
17. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
18. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
19. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
20. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
21. EMRseq : Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition
22. COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study
23. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
24. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
25. La tomografía por emisión de positrones en el estudio del nódulo pulmonar solitario
26. Positron Emission Tomography for the Study of Solitary Pulmonary Nodules
27. Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
28. Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.
29. Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.
30. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
31. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
32. Abstract PO-059: COVID-19 in melanoma patients: Spanish register
33. Activity Of Docetaxel, Carboplatin, And Doxorubicin In Patient-Derived Triple-Negative Breast Cancer Xenografts
34. Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patients
35. CheckMate 067: Long-term outcomes in patients with mucosal melanoma.
36. An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238)
37. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma:Results From the Phase IIIb/IV CheckMate 511 Trial
38. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
39. Lynch syndrome followed up in a hereditary gynaecological cancer unit.
40. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
41. An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).
42. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
43. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma
44. For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity
45. Deux schémas posologiques de l’association nivolumab (NIVO) plus ipilimumab (IPI) dans le mélanome avancé : résultats à 3 ans de l’étude CheckMate 511
46. Étude CheckMate 067 : résultats à 6,5 ans chez des patients atteints d’un mélanome avancé
47. Lynch syndrome followed up in a hereditary gynaecological cancer unit.
48. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
49. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).
50. Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.